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There is increasing evidence that modulation of tumor hyp-
oxia may improve therapy outcome. However, most preclini-
cal data are derived from subcutaneous rather than orthotop-
ic tumor models. We investigated the effect of the hypoxia-
modulating agents nicotinamide and carbogen on tumor hyp-
oxia, tumor blood perfusion, and proliferative activity in liver
metastases of the murine colon carcinoma line C26a. In un-
treated C26a liver metastases, we observed a considerable
amount of hypoxia, similar to the amount in liver metastases
of patients with colorectal cancer. Compared to untreated
mice, we observed a significantly smaller hypoxic fraction in
the liver metastases of mice treated with nicotinamide and
carbogen breathing as single treatments or in combination. In
the group of mice that underwent carbogen breathing, per-
fusion was significantly lower than in the untreated group, but
the decrease was only marginal. The proliferative activity was
similar in all groups. In C26a subcutaneous tumors, a similar
effect on hypoxia has been observed that was, however, com-
bined with a decrease in proliferative activity. The different
effects of nicotinamide and carbogen on parameters of the
tumor microenvironment in liver metastases and subcutane-
ous tumors suggest that the host tissue influences the mecha-
nism by which nicotinamide and carbogen exert their effects.
Since tumor hypoxia may be a clinical problem in colorectal
liver metastases, our results open possibilities for further re-
search on the effect of hypoxia modifiers on colorectal liver
metastases to improve therapy outcome. q 2005 by Radiation Research
Society
INTRODUCTION
It is well known that tumor hypoxia may decrease the
efficacy of both radiotherapy and chemotherapy (1), and
1 Address for correspondence: Department of Medical Oncology 550,
Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB
Nijmegen, the Netherlands; e-mail: h.vanlaarhoven@onco.umcn.nl.
there is growing evidence that modulation of tumor hypoxia
may improve treatment outcome (2). Preclinical studies on
modulation of tumor hypoxia and other parameters of the
tumor microenvironment such as vascularization, perfusion
and proliferative activity have been performed mostly on
subcutaneous tumors. However, several studies, particularly
on angiogenesis, have shown that the characteristics of the
host tissue may influence the tumor microenvironment (3).
Therefore, modulation of the microenvironment by nicotin-
amide and carbogen may have different effects in subcu-
taneous tumors and at sites of metastases. Recently, we
showed that tumor hypoxia in subcutaneous murine colon
carcinomas can be modified by administration of nicotin-
amide and/or breathing of carbogen (4). The liver is the
most common site for metastases of colorectal cancer, and
we have demonstrated extensive hypoxia in these colorectal
liver metastases (van Laarhoven et al., unpublished data).
Modulation of the tumor microenvironment of liver metas-
tases may therefore have important clinical consequences.
To assess the prospects of modulating the tumor microen-
vironment, we investigated the effect of nicotinamide and
carbogen in liver metastases of a murine colon carcinoma
line.
MATERIALS AND METHODS
Murine Liver Metastasis Model
C26a cells were acquired from Dr. G. J. Peters of the Vrije Universiteit
(Amsterdam, the Netherlands) and grown in DMEM 1 10% FCS. A total
of 100,000 cells were injected in the spleen of female BALB/c mice;
after 1 day, the spleen was removed to avoid local tumor growth. Animals
were kept according to institutional guidelines for animal care. Experi-
ments were performed 15 days after injection of the cells. Pilot experi-
ments had shown that at that time multiple metastases had developed in
the liver. All experiments were approved by the institutional ethical com-
mittee for animal use.
Nicotinamide and Carbogen
Nicotinamide (Sigma-Aldrich) (20 mg/ml) was injected intraperitone-
ally (ip) at a concentration of 500 mg/kg. For carbogen (95% O2, 5%
CO2, Hoek Loos, Schiedam, the Netherlands) breathing, the mice were
put in a Perspex box with a continuous carbogen flow of 5 liters/min.
Nicotinamide was administered 20 min before the start of carbogen
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breathing. Carbogen breathing continued for 30 min before the animals
were killed. The mice were treated with nicotinamide alone (n 5 4),
carbogen alone (n 5 5), or the combination of both (n 5 5). The effects
on tumor hypoxia, perfusion and proliferation were analyzed and com-
pared with a control group of animals kept under normal air breathing (n
5 4).
Markers of Hypoxia, Perfusion and Proliferation
Pimonidazole [1-((2-hydroxy-3-piperidinyl)propyl)-2-nitroimidazole
hydrochloride, Natural Pharmacia International, Belmont, CA] (5–7),
which is a bio-reductive chemical probe with an immuno-recognizable
side chain, was used as a marker of hypoxia. Pimonidazole (20 mg/ml)
was combined with the perfusion marker Hoechst 33342 (Serva, Heidel-
berg, Germany) (3.75 mg/ml), and 0.1 ml of this solution was injected
intravenously in the tail vein of each mouse. As a marker of proliferation,
the S-phase marker bromodeoxyuridine (BrdUrd) (Sigma-Aldrich,
Zwijndrecht, the Netherlands) (2.5 mg/ml) was injected ip at a dose of
0.5 ml. Pimonidazole/Hoechst and BrdUrd were injected 25 min before
the animals were killed by cervical dislocation. This time was chosen
because the maximum effect of nicotinamide on the blood perfusion has
been described 20 min after ip injection of nicotinamide (8), and for
carbogen the maximum effect on pO2 has been observed after 5 min of
carbogen breathing (9). Livers were removed immediately, cut in frag-
ments of approximately 6 mm, and stored in liquid nitrogen. Frozen sec-
tions 5 mm thick were cut for staining and further analysis.
Immunohistochemical Staining of Murine Liver Metastases
After thawing, the sections were fixed in cold (48C) acetone for 10
min. Then slides were scanned (see below) for the Hoechst 33342 signal
before immunohistochemical staining of the other markers. After scan-
ning of the Hoechst 33342 signal and between all consecutive steps of
the staining procedure, sections were rinsed three times for 2 min in PBS.
Sections stained for pimonidazole were mounted in Fluorostab (Organon,
Boxtel, the Netherlands), and the sections stained for BrdUrd were
mounted in phosphate-buffered saline (PBS). The first tissue section was
stained for endothelium plus the hypoxia marker pimonidazole. The sec-
ond consecutive tissue section was stained for endothelium and the S-
phase marker BrdUrd.
Endothelial structures and pimonidazole. After rehydration for 20 min
in PBS, sections were incubated with rabbit anti-pimonidazole (J. A. Ra-
leigh), diluted 1:800 in polyclonal liquid diluent (PLD, Euro-DPC, Breda,
the Netherlands), for 45 min at 378C. After incubation with donkey anti-
rabbitF(ab9)2-Alexa488 (Molecular Probes, Leiden, The Netherlands), di-
luted 1:400 in PLD for 45 min at 378C, sections were incubated with
undiluted 9F1, a rat monoclonal antibody to mouse endothelium, for 60
min at room temperature [Department of Pathology, Radboud University
Nijmegen Medical Center, the Netherlands (10)]. Finally, sections were
incubated for 30 min at 378C with chicken anti-rat-Alexa647 (Molecular
Probes) diluted 1:200 in PLD.
Endothelial structures and BrdUrd. DNA was denatured by incubation
for 10 min at room temperature in 2 M hydrochloric acid. The pH was
neutralized by rinsing the sections for 10 min in 0.1 M borax. Then
sections were incubated for 60 min at 378C with sheep anti-BrdUrd (Ab-
cam Ltd, Cambridge, UK) diluted 1:50 in PLD overnight at 48C. Then,
sections were incubated with donkey anti-sheep-Cy3 (Jackson Immuno
Research Laboratories) diluted 1:400 in PLD for 30 min at 378C. After
incubation with 9F1 for 60 min at room temperature, sections were in-
cubated 30 min at 378C with chicken anti-rat-Alexa647 (Molecular
Probes) diluted 1:200 in PLD. Finally, sections were incubated with Fast
Blue diluted 1:1000 in PBS for 5 min at room temperature.
Image Analysis
Quantitative data for tumor hypoxia, perfusion and proliferation were
acquired with a semiautomatic method based on a computerized digital
image analysis system that has been described previously and has been
shown to be an accurate and reproducible technique (11–13). Briefly, we
used a high-resolution intensified solid-state camera on a fluorescence
microscope (Axioskop, Zeiss, Weesp, the Netherlands) with a computer-
controlled motorized stepping stage to scan whole tumor cross sections
sequentially, with different filters for the detection of the fluorescence
signals. Analysis of hypoxia and vascular structures was performed with
1003 magnification, and analysis of proliferation was performed with
2003 magnification. Depending on the size of the tumor section, each
scan consisted of 36–144 fields of 1.2 mm2. One composite image was
reconstructed from the individual microscopic fields. A contour line was
drawn to delineate the tumor area, thereby excluding non-tumor tissue
(such as normal liver tissue and necrosis) from the analyses, using con-
secutive H&E-stained tumor sections. The hypoxic fraction of the tumor
section was computed as the tumor area stained by the hypoxia marker
relative to the total viable tumor area. The perfused fraction of the tumor
was defined as the area that was stained by both Hoechst 33342 and 9F1
(i.e. perfused vascular area) relative to the total vascular area. The relative
vascular area was calculated by dividing the 9F1-positive area by the
total viable tumor area. The BrdUrd labeling index was calculated as the
ratio of the BrdUrd-positive area and the total nuclear area.
Statistics and Calculations
The t test for independent samples was used to compare differences in
hypoxic fraction, perfused fraction, relative vascular area and labeling
index between different groups of mice.
RESULTS
In all mice, several metastases of about 2 mm were ob-
served in the liver. Figure 1 shows a small part of the liver
containing three metastases. No preference for a specific
lobe of the liver was noted, and no metastases were seen
in other organs. The metastases consisted of densely packed
tumor cells and stroma without clear structural organization
(Fig. 1A). In untreated mice, areas of hypoxia were found
throughout the metastases (Fig. 1B).
Microscopic examination showed that, compared to the
control group, less hypoxia was present in the liver metas-
tases that were treated with nicotinamide, carbogen or the
combination of nicotinamide and carbogen (Fig. 2). For a
quantitative analysis of hypoxia and vasculature, two or
three fragments of the liver per mouse were analyzed sep-
arately; for a quantitative analysis of the BrdUrd labeling
index, one fragment of the liver per mouse was used. Re-
sults of the quantitative analysis are shown in Table 1. A
significant decrease in hypoxic fraction was observed after
treatment with nicotinamide, carbogen and the combination
of nicotinamide and carbogen (P , 0.05; Fig. 3). Although
a significantly lower perfused fraction was observed in the
group of mice that underwent carbogen breathing compared
to the control group (P , 0.05), the decrease in the per-
fused fraction was only marginal, from 0.89 in control an-
imals to 0.83 in carbogen-treated animals. The relative vas-
cular area and BrdUrd labeling index were not significantly
different in the treated groups compared to the control
group.
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FIG. 1. Panel A: H&E scan of part of the liver of one mouse from
the control group that contained three liver metastases of C26a tumor.
Panel B: The corresponding liver metastases stained for hypoxia as in-
dicated by pimonidazole binding (green), perfusion (blue) and vasculature
(red-pink). The scale bar indicates 1 mm. Original magnification 1003.
FIG. 2. Binary maps of complete sections of C26a colon liver metastases without treatment (panel A) and after
nicotinamide administration combined with carbogen breathing (panel B). Vascular structures: red-pink; perfused
vessels: blue; hypoxic areas: green. The scale bars indicate 100 mm. Original magnification 1003.
DISCUSSION
In untreated C26a liver metastases, we observed a hyp-
oxic fraction of 0.12, which is similar to the amount of
hypoxia in liver metastases of patients with colorectal can-
cer (van Laarhoven et al., unpublished data). Recently, we
described hypoxia, vascularity and proliferative activity of
subcutaneous C26a tumors implanted in the flank of BALB/
c mice and the response to nicotinamide and carbogen (4).
Quantitative data for hypoxia and proliferative activity were
similar for the liver metastases and subcutaneous tumors of
the same tumor line. However, a larger relative vascular
area and a higher perfused fraction were observed in the
liver metastases compared to subcutaneous tumors (relative
vascular area: 0.05 compared to 0.02 and perfused fraction:
0.89 compared to 0.56, respectively, P , 0.05). Although
the time between the administration of Hoechst dye and
freezing of the tumors was relatively long (25 min), we
have established in this tumor model that the Hoechst dye
does not diffuse further than a few cell layers from the
vessel and does not influence the measured perfused frac-
tion. This time was chosen to monitor the distribution of
pimonidazole, which needs to be administered a minimum
of 25 min before animals are killed to allow for binding to
hypoxic cells. Since this time was used in both liver me-
tastases and subcutaneous tumors, it cannot explain the
large perfused fraction in liver metastases compared to sub-
cutaneous tumors. Since liver metastases were smaller than
subcutaneous tumors, it could be hypothesized that when
tumor growth is faster than growth of (functional) vascu-
lature, the perfused fraction decreases at larger tumor sizes.
Alternatively, the host vasculature may play a role in the
difference in perfused fraction between liver metastases and
subcutaneous tumors. The vasculature of primary tumors
and metastases may consist of neoangiogenic vessels or of
host vessels that have been co-opted by the tumor (14). If
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TABLE 1
Average Hypoxic Fraction, Perfused Fraction, Relative Vascular Area, and BrdUrd
Labeling Index 6 SD for all Liver Fragments of the Control and Treatment Groups
Treatment Hypoxic fraction Perfused fraction
Relative
vascular area Labeling index
Control 0.12 6 0.11 0.89 6 0.05 0.05 6 0.02 0.06 6 0.02
Nicotinamide 0.01 6 0.01** 0.89 6 0.07 0.04 6 0.02 0.13 6 0.07
Carbogen 0.03 6 0.03* 0.83 6 0.07* 0.05 6 0.02 0.09 6 0.06
Nicotinamide 1 carbogen 0.02 6 0.04** 0.87 6 0.10 0.04 6 0.02 0.09 6 0.04
Notes. Two to three sections from different locations in the liver per mouse from four or five mice were used.
* P , 0.05 compared with the control group; ** P , 0.01 compared with the control group.
FIG. 3. Quantitative assessment of the hypoxic fraction per liver frag-
ment in C26a liver metastases. Values are shown for control tumors and
for tumors after administration of nicotinamide, carbogen and the com-
bination of both. The horizontal line indicates the mean for each group.
C26a tumors mainly depend on co-option for their vascu-
larization, this would explain the larger perfused fraction
in liver metastases compared to subcutaneous tumors, since
the liver is an extremely well-perfused organ compared to
subcutaneous tissue. In the subcutaneous tumors, we ob-
served a hypoxic rim, possibly caused by pressure of the
surrounding tissue on the small C26a tumor vessels, re-
sulting in compression of vasculature, thereby hindering tu-
mor blood perfusion and leading to hypoxia. In the liver
metastases model used in this study, we did not observe a
hypoxic rim, which is probably due to reduced tissue pres-
sure in the liver compared with overlying skin.
To assess the feasibility of modulating tumor hypoxia,
we investigated the effect of nicotinamide and carbogen in
C26a liver metastases. A significant decrease in hypoxic
fraction was observed after treatment with nicotinamide
and carbogen as single agents as well as after the combi-
nation treatment, similar to our previous findings for sub-
cutaneously implanted C26a tumors (4). It should be noted
that except for the murine C26a and C38 colon carcinomas,
a reduction in hypoxic fraction of this magnitude after ad-
ministration of nicotinamide as a single agent has not been
observed in experimental tumors before.
Several mechanisms could play a role in the observed
decrease in hypoxia in liver metastases. For nicotinamide,
the classical hypothesis is that a decrease in hypoxic frac-
tion can be attributed to an improved tumor perfusion (15)
by suppression of transient fluctuations in microregional
blood flow (16). Although in our experiments no increase
in perfusion of the liver metastases was observed, these
transient fluctuations may not have been picked up by the
current protocol, where we chose an interval of 25 min
between nicotinamide and Hoechst dye administration. Pre-
viously, we have suggested that nicotinamide may decrease
hypoxia in C26a tumors by increasing blood glucose (4),
possibly by induction of glycogen breakdown (17, 18). The
so-called Crabtree effect (19), which refers to a decrease in
cell respiration rate after addition of glucose, would be ac-
companied by a decrease in proliferative activity, due to
enhanced anaerobic glycolysis, leading to an overproduc-
tion of lactic acid that may disrupt tumor development.
However, in liver metastases no decrease in BrdUrd label-
ing index was observed, and therefore the Crabtree effect
does not appear to occur. This suggests that the host tissue
may have some influence on the mechanism by which nic-
otinamide exerts its effects.
For carbogen, it has been proposed that increased oxygen
transport by the plasma causes a decrease in tumor hypoxia
(20). This decrease in tumor hypoxia has also been de-
scribed as being a result of the so-called vascular steal ef-
fect (21). In tumor vasculature, which lacks responsive
smooth musculature and which is arranged in parallel with
the host vasculature of surrounding normal tissue, carbogen
breathing can cause a reduction in tumor blood perfusion.
This is due to the vasodilating effect of the CO2 component
of carbogen on host vessels in the surrounding normal tis-
sues, ‘‘stealing’’ blood from the tumor. Hence the reduced
supply of nutrients would decrease the O2 consumption rate
of tumor cells and decrease the hypoxic fraction (9). How-
ever, in liver metastases, tumor vasculature, especially
when it consists of co-opted host vessels, is more likely to
be in series with host vasculature rather than in parallel.
Therefore, it is unlikely that a vascular steal effect plays an
important role in the observed decrease in hypoxic fraction.
Although the reduction in hypoxic fraction caused by
nicotinamide and carbogen in liver metastases seems to oc-
cur through different mechanisms (suppression of fluctua-
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tions in blood flow and increased plasma oxygen transport,
respectively), the magnitude of the effect was similar.
Since tumor hypoxia has been related to poor prognosis
due to progression to a more malignant phenotype and in-
creased resistance to therapy (22), it has become a central
issue in cancer treatment. Clinical studies in several tumor
types (23–26) have shown promising results with the com-
bination of hypoxia modulation and radiation therapy. For
advanced colorectal cancer, chemotherapy is often the treat-
ment of choice. A variety of direct and indirect mechanisms
have been described by which hypoxia can decrease che-
motherapy efficacy (27). For example, shutdown of blood
vessels (acute hypoxia) and increased diffusion distances
(chronic hypoxia) diminish the distribution of chemother-
apeutic agents. Other mechanisms include an increased ac-
tivity of DNA repair enzymes and increased invasiveness
and angiogenic potential. In this study, we observed in an
orthotopic murine model that hypoxia is present in liver
metastases of colon carcinoma and that hypoxia can be de-
creased using nicotinamide and carbogen. Further experi-
ments will show whether the combination of these hypoxia
modifiers with chemotherapy can improve the outcome of
treatment of advanced colon cancer.
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